EDGAR·FLOW

HARVARD BIOSCIENCE INC — Form 8-K

Filed November 10, 2026 · analyzed by the 8-K Agent
8-K — Neutral significance 72/100
What the filing says
In December 2025, Harvard Bioscience refinanced ~$40M in debt (Term Loans A, B, C from BroadOak Capital), extending maturity to December 2029 with blended interest rates ranging 12.50%–12.80% (first 2 years), achieving $3M in annual cash savings. Separately, Project Viking—announced Q1 2026—consolidates U.S. manufacturing from Holliston, MA to Minneapolis over 15 months (completion Q1 2027), targeting $3M adj. EBITDA improvement in 2027 and $4M/year thereafter. 3Q26 revenue was $22.2M (+8% YoY); FY26 guidance lowered to 3–5% growth and (1%)–4% adj. EBITDA growth (vs. prior 6–10%). BroadOak received warrants for 200K shares at $5/share and board nomination rights.
Why this rating

Refinancing + restructuring both material to $18.2M market-cap firm (debt $37M = 204% of market cap). Extends runway, saves cash, but guidance cut signals near-term headwinds; consolidation unlocks long-term margin, yet near-term execution risk and dilution (warrants) present.

Price action (we called it neutral)
at our read · unknown
$9.02
+10 min · unknown
$8.60 ▼ 4.66%
+30 min · unknown
$9.10 ▲ 0.93%
+1 hr · unknown
$9.10 ▲ 0.89%
+4 hrs · unknown
$9.13 ▲ 1.27%

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ HBIO · stock on Yahoo Finance ↗

See more from November 10, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.